Figure 2 from Screening FDA-Approved Oncology Drugs with Three-Dimensional Spheroids Identifies Romidepsin as a Therapeutic Candidate for Osteosarcoma
<p>Top hits of initial screen are HDIs, proteasome inhibitors, and topoisomerase inhibitors. <b>A,</b> Screen of FDA-approved oncology drugs on sarcospheres generated from 143B, MG63.3-GFP, and LM7 cell lines. Heatmap shows inhibition of growth in blue and little or no effect in re...
Αποθηκεύτηκε σε:
| Κύριος συγγραφέας: | |
|---|---|
| Άλλοι συγγραφείς: | , , , , , , , , , , , , , , , , , , , , , |
| Έκδοση: |
2025
|
| Θέματα: | |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|
| Περίληψη: | <p>Top hits of initial screen are HDIs, proteasome inhibitors, and topoisomerase inhibitors. <b>A,</b> Screen of FDA-approved oncology drugs on sarcospheres generated from 143B, MG63.3-GFP, and LM7 cell lines. Heatmap shows inhibition of growth in blue and little or no effect in red. Colored bars on left of figure indicate control or drug class. Results of unsupervised clustering analysis are shown at the bottom of the figure. Sarcospheres were screened with the individual drugs (10 μmol/L) both with and without MAP chemotherapeutics for 48 hours. All wells contained 0.1% DMSO as vehicle. Growth was assessed by change in metabolic activity during the 48-hour treatment period. 0% represents stable disease since the start of treatment, 0% to 100% represents progression in which 100% is the untreated control, and values less than 0% represent regression for which −100% represents blank wells without sarcospheres. <b>B,</b> Summary of the initial screen showing the mean of the rows for each drug in <b>A</b>.</p> |
|---|